Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
September 27, 2006 06:00 AM Eastern Time
Biophan Announces Congressional Approval of $1 Million Allocation in New Government Grants in Support of MYO-VAD™ Cardiac Recovery System
BIOWIRE 2K...
ROCHESTER, N.Y.--(BUSINESS WIRE)--Biophan Technologies, Inc. (OTCBB: BIPH - News; FWB: BTN), a developer of next-generation medical technology, announced today full congressional approval of an allocation of $1 million in U.S. government funding to help accelerate the commercialization of the MYO-VAD™ cardiac recovery system. A previously announced additional allocation of $400,000 is still pending.
The U.S. Congress approved the expenditure on September 26, with the passage of the Department of Defense Appropriations Bill for Fiscal Year 2007. The MYO-VAD cardiac recovery system is being developed to provide short-term support and recovery capability to damaged or diseased hearts.
“This appropriation will help extend the availability of our technology to heart failure patients at locations outside of the very limited number of specialized hospitals, including suburban or rural areas and advanced military units,” said Jeffrey L. Helfer, President of Biophan’s Cardiovascular Division.
"We are very pleased with this validation of the importance and value of our research and development in the MYO-VAD, which is aimed at one of the largest and fastest-growing medical market segments," said Michael Weiner, Biophan CEO. "The MYO-VAD offers new hope for patients with heart failure, a leading cause of death in the United States."
The MYO-VAD is the first in a family of products based on Direct Mechanical Ventricular Actuation (DMVA) technology. It consists of a flexible polymer cup that fits around the heart, coupled to a drive unit, which pumps the heart to restore blood flow. Due to its simple design, rapid and technically simple installation, and anticipated lower total procedure cost, management expects the MYO-VAD to become a broadly available option for treating many types of heart failure. Because it does not come into direct contact with circulating blood, the MYO-VAD promises to provide substantial advantages over today’s cardiac assist devices by eliminating serious and potentially fatal problems, including stroke, bleeding, and infection.
About Biophan
Biophan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI). Having solved problems related to MRI safety and image compatibility for patients with implanted medical devices, the Company licenses its technologies to leading device manufacturers. The Company's mission has expanded to provide other technologies which will improve the delivery of healthcare. Biophan's technologies enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. The Company is helping to commercialize the MYO-VAD(TM), a new, MRI-compatible ventricular assist device which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors hold 56 issued U.S. patents and over 100 U.S. and international patents pending. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN. For more information on Biophan please visit our website at www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements within the meaning of applicable securities laws. These statements reflect what Biophan anticipates, expects, or believes may happen in the future. Biophan's actual results could differ materially from the outcome or circumstance expressed or implied by such forward-looking statements as a result of a variety of factors including, but not limited to: Biophan's ability to develop its technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the ability of Biophan to demonstrate the effectiveness of its technology; the acceptance by the market of Biophan's technology and products incorporating such technology, the ability of Biophan to effectively negotiate and enter into contracts with medical device manufacturers for the licensing of Biophan's technology; competition; the ability of Biophan to raise capital to fund its operating and research and development activities until it generates revenues sufficient to do so; and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC, which are incorporated herein by reference. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Contacts
Investor Relations:
PR Financial Marketing
Jim Blackman, 713-256-0369
jimblackman@prfinancialmarketing.com
or
Media:
Biophan Technologies, Inc.
Carolyn Hotchkiss, 585-214-2407
chotchkiss@biophan.com
BIPH paid for it, but at least its positive-
Print this Release
September 26, 2006 12:30 PM Eastern Time
Dutton Associates Announces Investment Opinion: Biophan Technologies Speculative Buy Rating Reiterated by Dutton Associates
NOTE TO EDITORS: The following is an investment opinion issued
by Dutton Associates
EL DORADO HILLS, Calif.--(BUSINESS WIRE)--Dutton Associates continues its coverage of Biophan Technologies Inc. (OTCBB:BIPH) reiterating its rating of Speculative Buy and 12-month price target of $3.00. The 14-page report by Dutton Associates senior analyst Richard W. West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg, Zacks, Reuters, Knobias and other leading financial portals. Biophan has developed and owns proprietary technologies for safely enabling implantable biomedical devices for use in diagnostic and interventional procedures that are compatible with MRI instruments. Biophan is developing technologies for: improving MRI contrast agents, improved drug elution, drug delivery systems, an MRI-safe and imaging-compatible ceramic motor, a system for generating power for implantable devices from body heat, and a series of implantable devices, including an MRI-compatible vena cava filter. Biophan's strategy is to develop and patent technologies. Biophan does not manufacture; rather, it endeavors to license its technology to third party manufacturers of medical devices, and its future revenue will come from license royalty fees.
About Dutton Associates
Dutton Associates is one of the largest independent investment research firms in the U.S. Its 28 senior analysts are primarily CFAs, and have expertise in many industries. Dutton Associates provides continuing analyst coverage of 140 enrolled companies, and its research, estimates, and ratings are carried in all the major databases serving institutions and online investors.
The current cost of enrollment in our one-year continuing research program is US $39,500 prepaid for 4 Research Reports, typically published quarterly, and requisite Research Notes. Dutton Associates received $35,000 from the Company for 4 Research Reports with coverage commencing on 04/13/06. The Firm does not accept any equity compensation. Our principals and analysts are prohibited from owning or trading in securities of covered companies. The views expressed in this research report accurately reflect the analyst's personal views about the subject securities or issuer. Neither the analyst's compensation nor the compensation received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosures and analyst background at www.jmdutton.com before investing.
Press Release Source: CEL-SCI Corporation
CEL-SCI CEO Interviewed by Wall Street Reporter
Tuesday September 26, 10:00 am ET
VIENNA, Va., Sept. 26 /PRNewswire/ -- CEL-SCI CORPORATION (Amex: CVM - News), a drug development company with its lead cancer product cleared for a Phase III trial, today announced that Chief Executive Officer, Geert Kersten is featured in an interview with the Wall Street Reporter. Interested parties may go to http://www.wallstreetreporter.com to access the interview. The Wall Street Reporter is a premier information source for professional investors seeking successful new investment ideas.
ADVERTISEMENT
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine® is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI's other products, which are currently in pre- clinical stage and are funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
rbl100, yeah I just wanted to see what securities-laws would answer with. After I busted him he evidently ran back under a rock-did not answer,lol.
Thats strange securities-laws, over on RB you say SLJB is a scam. Changed your mind????
Thanks brent, and looks as if AURC news also hwlped NDOL.
Casprs1-Send me $1000 via my PayPal account and I will give you Rawnocs acct. info , you will then become a Suljaire :).
"GOOD NEWS", "GOOD NEWS"-
er, ah, was this UNLIKE last "Good News" (AF) PR,lol.
Re: SLJB-
Sulja Bros. Building Supplies Ltd. Releases Update on Audit
Sep 25, 2006 3:08:00 PM
WINDSOR, ON -- (MARKET WIRE) -- 09/25/06 -- Sulja Bros. Building Supplies Ltd. (PINKSHEETS: SLJB) releases updates to shareholders on the delay of the audit.
Sulja Bros. today announced that there will be a slight delay in posting the audited financials as stated in previous press release in order to conform with proper accounting practices. A company spokesperson stated, "The delay is nothing to worry about, we want to make sure that when the audits are posted they are done properly and make complete sense. Since these audits include North American companies and figures generated from the Middle East operations, we had to make sure that all companies under the Sulja Bros. umbrella operation are taken in consideration. Also, we have to ensure that these final audits meet all necessary standards and legal requirements as stated in all these different regions. We apologize for the delay but we have taken the liberty to decide that posting complete and all-inclusive financials audits would be a better course of action rather than hastening to complete only portions of it.
"We understand the frustration that our shareholders might feel and apologize again for this delay."
This contains forward-looking information within the meaning of The Private Securities Litigation Act of 1995. Forward-looking statements may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," or statements indicating certain actions: "may," "could," "should" or "might occur." Such forward-looking statements involve certain risks and uncertainties. The actual result may differ materially from such forward-looking statements. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results (expressed or implied) will not be realized.
http://www.cafepress.com/bullnbear_shop
34/54-up .05 as we speak :)
More AURC news today-
AURUS Concludes US$10 Million Offering to NewConsult Ltd., a Swiss Private Equity Fund
By Market Wire
Last Update: 9/25/2006 1:58:54 PM Data provided by
NEW YORK, NY, Sep 25, 2006 (MARKET WIRE via COMTEX) -- Aurus Corporation (PINKSHEETS: AURC) announced today that it has concluded a $10,000,000 US offering to NewConsult Ltd., a Swiss private equity fund.
According to the offering, NewConsult Ltd. will proceed to fund an initial US$2 million upon the company's listing on the Frankfurt Stock Exchange, which is expected by the middle of October and will continue to fund the company's operation for a period of 48 months. NewConsult Ltd. has also received a right of first refusal for any subsequent funding of up to US$50,000,000.
"The funding by NewConsult Ltd. will enable us to immediately increase production and purchase all the equipment needed to mine our reserves," said Gerald Parkin, President of Aurus Corporation. "The $10,000,000 funding can easily turn into a $50,000,000 financing based on our performance and the price of gold and in return create substantial value for our shareholders,'' further added Mr. Parkin.
About Aurus Corporation
Aurus Corporation is a publicly traded mining holding company with several precious metal properties with over 5 million ounces in gold reserves, trading under the ticker symbol AURC on the US Pinksheets market. Aurus seeks to continue to acquire proven gold and other precious metal reserves in Russia and other emerging counties and operate its mines through joint ventures and/or partnerships.
About NewConsult Ltd.
NewConsult Ltd. is a private equity fund based in Zurich, Switzerland, which specializes in undervalued commodity assets.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
SOURCE: Aurus Corporation
100% correct!
Posted by:
Moneynmetals
In reply to: None Date:9/24/2006 11:28:33 AM
Post #of 93171
This board has been comical the last 24 hours. Each side beating each other over the head with their point of view.
Keep posting responses to blatant bashers or pumpers and you keep them in work. Is this to hard to figure out people
Last I heard chad was hanging around in Florida :)
brent, have a great time and dont lose all your money because there are some stocks out there to bet on.
34/54, I was really surprised as the news hit early yesterday morning. Hope it continues Monday.
This was directed at all "worms":
Dear Sir or Madam:
Thank you for your recent e-mail to the group electronic mailbox of the Division of Enforcement at the United States Securities and Exchange Commission in Washington, D.C. We appreciate your taking the time to write to us. This automated response confirms that the Division of Enforcement has received your e-mail. You can rest assured that an attorney in the Office of Internet Enforcement will review your e-mail promptly.
We are always interested in hearing from members of the public, and you may be assured that the matter you have raised is being given careful consideration in view of the Commission's overall enforcement responsibilities under the federal securities laws. It is, however, the Commission's policy to conduct its inquiries on a confidential basis -- so this may be the only response that you receive. If your complaint is more in the nature of a consumer complaint (such as a dispute with your broker or a problem with your brokerage or retirement account), you should contact our Office of Investor Education and Assistance -- they may be able to help you. You may reach the Office of Investor Education and Assistance via telephone at (202) 551-6551or through the Web at HYPERLINK "http://www.sec.gov/complaint.shtml"www.sec.gov/complaint.shtml.
The Commission conducts its investigations on a confidential basis to preserve the integrity of its investigative process as well as to protect persons against whom unfounded charges may be made or against whom the Commission determines that enforcement action is not necessary or appropriate. Subject to the provisions of the Freedom of Information Act, we cannot disclose to you any information which we may gather and we cannot confirm to you the existence or non-existence of an investigation, unless made a matter of public record in proceedings brought before the Commission or in the courts.
If you are unsure where you should direct your inquiry or you want to learn more about how the SEC handles inquiries and complaints, please visit the SEC Complaint Center at HYPERLINK "http://www.sec.gov/complaint.shtml"www.sec.gov/complaint.shtml.
Should you have any additional information or questions pertaining to this matter, please feel free to communicate directly with us at HYPERLINK "mailto:enforcement@sec.gov"enforcement@sec.gov.
We appreciate your interest in the work of the Commission and its Division of Enforcement.
Very truly yours,
S/
John Reed Stark
Chief, Office of Internet Enforcement
United States Securities & Exchange Commission
Thanks todd, for post of the week!
CEL-SCI CEO Interview Published by SmallCap Network
By PR Newswire
Last Update: 9/22/2006 11:30:47 AM Data provided by
VIENNA, Va., Sept 22, 2006 /PRNewswire-FirstCall via COMTEX/ -- CEL-SCI Corporation (CVM) conducted an interview with SmallCap Network that was published Friday morning, September 22, 2006. The interview with the CEO of CEL-SCI, Geert Kersten, is in a question and answer format that addresses the current operations and future prospects of the Company. Interested parties may go to http://smallcapnetwork.net/archive/listserv/20060922-1.html to read the interview.
The SmallCap Network is a leading financial publisher dedicated to providing investors with information on equities in the small cap sector. They publish a weekly financial newsletter via email. The newsletter focuses on stocks in the small cap sector that have the potential to appreciate significantly in the future. With over 900,000 members, the SmallCap Network is one of the fastest-growing financial newsletters on the Internet.
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland. The Company's lead product Multikine(R) is cleared to enter global Phase III clinical trials in advanced primary head and neck cancer patients. CEL-SCI's other products, which are currently in the pre-clinical stage and are funded with U.S. government support, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense and avian flu.
SOURCE CEL-SCI Corporation
This is interesting. A while back I emailed suljabros. Today I received this spam email. Did anyone else receive this?
From: "dubaisupplyco@gmail.com" <dubaisupplyco@gmail.com> Add to Address Book Add Mobile Alert
To: XXXX@yahoo.com
Subject: Marine, Industrial and Oilfield supplies
Date: Fri, 22 Sep 2006 01:29:32 +0400
For all kinds of Project Supplies
We supply all kinds of project requirements: Marine, Industrial and Oilfield supplies
Dubai Supply Co.
From RB board by MDface:
By: mdface
22 Sep 2006, 10:38 AM EDT
Msg. 5251 of 5252
Jump to msg. #
Interesting read in Small Cap Digest. It came to my email so had to cut and paste:
Q. You regularly send open letters to shareholders about your company and its stock, including one on Wednesday (see below). Most corporations wouldn't bother, so why do you do that?
A. It's a combination of logic and heart. Stock owners want and deserve to know how a company is creating value for them. So, the letters accomplish that in an efficient and logical fashion. All of those letters are also from the heart. I think it's important for investors to know how CEL-SCI believes in the value and potential of its work, and equally, how we carefully evaluate the data before we move forward.
Q. Has it been worth the effort?
A. Yes, it's been worth it, which is why I've been writing those letters for ten years now. It takes a long time, but, in the end it will be soooo sweet. Investors have to understand that there's a difference between big biotech companies and the small and mid cap ones. Big biotech companies are already perceived as a proven entity to the investment community since they have sales and, mostly, profits. Small-cap and mid cap biotech companies, on the other hand, need to prove themselves over and over again as they work through all the pains of developing novel products. Just imagine how forward looking one has to be to develop a new drug. You can only get a patent, a prerequisite for raising money, if you have an idea that is totally novel and unique. Then you have to go out and explain your idea. The letters let us do that.
Multikine - CEL-SCI's Cancer Treatment
Q. And for CEL-SCI, the main drug in development is Multikine. Can you tell us - in simple terms - what it is and how it works?
A. Multikine is an immune system boosting drug that has shown very promising survival results in Phase II studies in head and neck cancer, which has been our focal point in the first part of our research. Think of it as an immune system booster that is a copy of a patient's own immune system. By switching the type of immune cell that attacks the tumor, Multikine helps the body break tumor tolerance - a scenario where the immune system does not actively attack the tumor. With Multikine you have a different and more effective immune response. It's a non-toxic way to help you beat cancer.
Q. You mentioned that Multikine is non-toxic. What does that mean?
A. It means that it does not cause bad things to happen to you as do radiation and chemotherapy, and many other products.
Q. And has human testing shown positive results?
A. It certainly looks that way. So far, 12% of the patients had no tumor remaining after only a 3 week treatment and 3.5 years after the whole cancer treatment was finished, survival with Multikine appeared to be much higher. In our Phase II testing we saw a 65 - 70% chance of survival with Multikine, or only a 50% chance without it. Phase III will look to verify these early results in a large number of patients. If we are right there will be many less deaths from cancer since more patients will be cured with the first treatment.
Q. How does Multikine differ from other similar treatments in development stages out there?
A. We know of no pharmaceutical drug that works like our product and attacks the tumor the same way.
The Opportunity
Q. Sounds like CEL-SCI is working on something unique. Why do you think bigger, well-funded companies aren't going down the same treatment avenue?
A. We have the area patented and they are blocked from doing this. They are starting to show an interest since we are about to enter Phase III clinical trials.
Q. Why do you not go for the chronic cancer treatment market as do so many of the pharma companies?
A. With our drug, if proven successful, it's possible to get the cancer with the first treatment and make a lot of money too. While the market for chronic cancer therapy is immense, our market is still huge and we should save the healthcare system money; therefore insurance companies should push for our product to be used. Our first goal is to beat cancer...the money will come when we get this product to market, and, if we are right, there will be plenty to go around.
Q. And what kind of market is out there? Are we talking $1 million, or $1 billion?
A. Each year, globally, there are 500,000 new diagnosed cases of head and neck cancer. Assuming Multikine is used to treat just 10% of them, at about $25,000 per patient, that would mean about $1.25 billion in sales. Obviously these are estimates, but that should give you some idea.
Q. That's enormous potential.
A. Yes, and in the biotech business, margins are very high. So, the potential earnings for shareholders are also enormous. That is why I have been buying the stock during the last 2 years. To get the maximum benefit, the time to invest, in my opinion, is now when the stock price is depressed. I believe that we have a risk/reward proposition in CEL-SCI which is very attractive.
Q. You said the average Multikine treatment per patient would cost around $25,000? That seems very low for a new cancer therapy.
A. It is low compared to many of the existing drugs, many of which show very small survival benefit. That's one of the other exciting parts of our cancer treatment. If we are right, Multikine will save lives and money. Medical expenses for a terminal cancer patient in the last year of his or her life total about $1 million. If we can reduce the number of patients getting to that terminal stage, we will help patients, insurance companies and the government payors.
CEL-SCI Shares
Q. It certainly seems like Multikine could eventually be an answered prayer for cancer patients, but let's talk a little bit about what this all means for shareholders. You contend that now is a good time to consider investing in CEL-SCI. Why now?
A. More so than most markets, biotech stocks are cyclical. Biotech followed pharmaceuticals lower for the last few years, but if you look at Pharma now, you can see they're on the rise again. That should help boost biotech stocks as well. But, I've also noticed how the smaller and mid cap biotech companies move in their own three-year (or so) cycle. This has been true for over 15 years. As of right now, we're at the low and long end of the down cycle, and overdue for the expansion (price appreciation) period. I see biotech coming out of its lull soon...especially with oil stocks and other sectors starting to fall out of favor. Investors are going to put their money somewhere, and I think biotech is starting come into favor. But that's not the only reason that now might be a good time... We are entering Phase III clinical trials and that is when institutional investors generally take positions.
Q. Any other reason now may be a good time to look at CEL-SCI?
A. My first and foremost goal - at all times - is to create shareholder value. We can do that by doing things the right way, and doing them when we're properly funded. We recently got $8 million in funding through the sale of shares when they were priced at 86 cents, while the overall market and biotech was suffering. But, just think of the kind of funding we can get when the market and biotech stocks are moving higher. It's best to wait for the right environment before making a major funding effort. Maintaining shareholder value is the motivating factor behind the decision. Doing the smart thing right now creates the most value later on and, in my opinion, it pays to be thoughtful and careful when you work in a high risk/high return field. I have seen too many small companies rush forward to get things done quickly, and, almost all of them are no longer around. You get to be big and successful only if you are thoughtful and careful.
Q. But some investors might say they'll wait until the stock actually starts to move higher before they buy in. What do you say to them?
A. I believe that waiting potentially means a missed opportunity. What if we get a big pharmaceutical partner? What if our bird flu drug is shown to work and bird flu hits the US? Once small biotech company stocks start to move (for whatever reason), you typically cannot catch them unless you are willing to pay up a lot. There have been days when our stock doubled. We have spent $90 million to get to this advanced point of development and our Company is valued at only $50 million. I believe that the ground-floor opportunity is here and now and I have invested in CEL-SCI accordingly.
Q. Is there anything else you think investors would want to know before we wrap-up?
A. To repeat something I mentioned earlier, my primary goals are to help cancer patients and to create shareholder value. There are several steps to achieving this: One of them is funding the operation when the time is right, keeping dilution down. Another one is communicating CEL-SCI's plan and progress on a regular basis. And obviously, one of the best ways to create value is in developing a more effective cancer treatment. Survival is the difference; Multikine has shown great results so far. We're excited to be on the track we're on, and we hope investors are able to see the big picture of Multikine's potential. Today we are valued at $50 million, and if we are right, we should be valued at between $1-3 billion when our drug comes to the market. Somewhere between $50 million and $1-3 billion is a lot of room for share appreciation, but it will not all happen the day we show the results from the Phase III study. So, don't assume Multikine has to be in approved, full-blown production to benefit shareholders. As you guys at the SmallCap Digest say, you buy a stock for where the company is going, not where they've been.
Editor: We couldn't agree more.
Kersten's recent letter to shareholders is below.
Dear Fellow Shareholders:
Many of us invest in biotechnology because of its life changing possibilities and its enormous potential for financial return. We all know that the development of a biotech drug takes a long time, is difficult and costs many millions of dollars. Yet most of us are willing to wait for the potential "home run" on our investment as long as the data looks good. However, the cyclical and at times completely illogical treatment of biotechnology stocks by the investment community challenges the commitment of even the most dedicated of investors.
For this reason we are very pleased to point out that CEL-SCI's share price has outperformed the vast majority of its small and mid cap brethrens, albeit with enormous cyclical volatility, over the last few years. Since high volatility will never be eliminated from biotech stocks like CEL-SCI, we must learn to use it to our advantage. I recently purchased more stock in the open market because I believe that the present price represents a great opportunity.
In the spring of 2003 CEL-SCI's financial health looked rather bleak, our stock price hit an all time low and few people believed in our ability to survive, much less rebound. Nevertheless, despite a stock market environment that has been quite unfriendly to small and medium sized biotechnology companies like ours, we have managed to put ourselves on good financial footing and increased our share price by several hundred percent; and that is after CEL-SCI's stock price pulled back from its substantially higher level in the spring of 2006. We survived, and indeed improved our position by persistently and carefully following our plan for building shareholder value and obeying the following rule. "FOLLOW THE DATA, THE DATA NEVER LIE."
The data for CEL-SCI's products point to a very positive future for our company. Furthermore, based upon our most recent survival data and our cautious and deliberate way of proceeding, we believe that we will continue to build value for our shareholders. Management's sizable investment in CEL-SCI gives us added incentive to do so.
We aim to make the first line cancer treatment more successful through the addition of our cancer drug Multikine(r). Multikine will be a major breakthrough in therapy for cancer patients if we can confirm the increased patient survival data from our Phase II clinical studies in the planned global Phase III clinical study that has already received the go-ahead by the Canadian authorities. Simplistically, would you rather have a 65 - 70% chance of survival with our Multikine or a 50% chance of survival without our Multikine? When we can prove this kind of clinical benefit to patients, shareholder value creation will need no further explanation.
We believe that the market for Multikine may quickly expand beyond the original head and neck cancer indication. The product has already been shown to be very safe, and it is very probable that clinical trials will be conducted with Multikine to examine its usefulness in treating other diseases in which the affected patients might benefit by the addition of Multikine to their overall treatment. Furthermore, the use of Multikine, especially in cancer, would save the health care system money, most likely a lot of money, as fewer patients will have recurrence of their cancer, and thus fewer patients will need to be treated. In short, Multikine could become a very important addition to current cancer treatments.
In the last 18 months we have achieved a number of very important milestones for Multikine. We have published the mechanism of action in the Journal of Clinical Oncology, a highly recognized, leading peer-reviewed cancer publication. We have been granted an important new patent on Multikine, and we received a no objection letter (NOL) from the highly regarded Canadian regulators for our Multikine Global Phase III head and neck cancer clinical trial. Last, but not least, we presented data at the "Vaccine Discovery and Commercialization" conference in Philadelphia which indicate that the addition of Multikine prior to the standard of care treatment resulted in a 33-40% improvement in the median survival at 3 1/2 years after surgery. Survival is the "gold standard" for testing in cancer.
Our CEL-1000 drug has also received a fair amount of attention. It has shown protection in animals against a number of diseases such as herpes virus, viral encephalitis, malaria and leishmania. Based on these data, the U.S. government became interested in its potential for use against avian flu. We believe that CEL-1000 may have the best avian flu potential in two areas, one, as an adjuvant to make vaccines more effective and two, as an adjunct to other antiviral therapies. Either of these uses holds great promise for CEL-1000 as a product.
We cannot say that the past years have been without difficulties, far from it, but we have been able to overcome any obstacles that we have encountered. We believe that future obstacles will also be dealt with in the same manner. If developing new medicines for cancer were easy, cancer would have been defeated long ago; after all, President Nixon declared the war on cancer 36 years ago. Yet cancer is the second leading cause of death in the U.S. today and, if the trend continues, it is expected to become the leading cause of death in the next few years.
Today we continue to believe that our CEL-SCI shares are not fully valued by the market place, an unhappy occurrence for existing shareholders, but a great opportunity for new shareholders. This is not an uncommon phenomenon in biotechnology investing and was seen often during the early days of Amgen or Genentech, today's leading biotechnology companies. Now almost everybody wishes that they had been long-term investors in Amgen or Genentech since these companies turned out to be great investments. In hindsight the successes of these biotech leaders may appear to have been easy, but an examination of their early history reveals that things did not always go their way. Until 2003 Genentech seemed to be the only one who believed in Avastin, its new blockbuster cancer drug. These companies succeeded because they were persistent and they followed the data. We plan to do the same.
What is the value of a non-toxic cancer drug that enhances survival? To cancer patients it is immeasurable. To investors it is so big that they want to be invested in the company that owns it. That is why I have invested so much of my own money in CEL-SCI, with new stock purchases just a short time ago.
Our Phase II data suggest that we have a cancer compound that may significantly increase survival in patients with advanced primary head and neck cancer. Our Phase III trial is meant to prove this survival benefit in a statistically significant manner to get Multikine approved for sale.
In short, we hope to be able to build significant shareholder value by conducting our important work in a deliberate and methodical manner and always following the data. This has worked for us in the past few years and it should continue to work for us in the future as well. We thank you for your support.
Calypte Biomedical Corporation announces Russian approval of Aware Oral Fluid HIV tests
By M2
Last Update: 9/22/2006 4:47:27 AM Data provided by
Sep 22, 2006 (M2 EQUITYBITES via COMTEX) -- Calypte Biomedical Corporation (CBMC), a manufacturer of medical diagnostic tests, declared on 21 September that it has received approval for its Aware Oral Fluid (OMT) HIV-1/2 rapid test for both PRO and OTC markets in the Russian Federation.
The Russian Federation is the second market, following the United Arab Emirates, to approve the use of an HIV-1/2 test in OTC settings, permitting significantly greater access to HIV testing in these countries, Calypte said.
Can someone give me a quick rundown on SLJB and yesterdays PR re. share count? I was away from computer since noon yesterday and cannot read 2000+ new posts from sljb board. Did the PR cause SP to decline? TIA.
Calypte Announces Russian Federation Approval of Oral Fluid HIV Tests
Thursday September 21, 8:00 am ET
LAKE OSWEGO, Ore., Sept. 21 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market announced today that it has received approval for its Aware(TM) Oral Fluid (OMT) HIV-1/2 rapid test for both PRO and OTC markets in the Russian Federation. The Russian Federation is now the second market, following the UAE, to approve the use of an HIV-1/2 test in OTC settings, permitting significantly greater access to HIV testing in these countries.
ADVERTISEMENT
The approval has been entered into the State Register of Articles of Manufacturing for Medical Purposes and Medical Technology and is valid through August 10, 2011. The approval was granted by the Minister of the Federal Service of Health Care and Social Development Control of the Ministry of Health of the Russian Federation.
Mr. Roger Gale, Calypte's Chairman and Chief Executive Officer stated, "We have worked closely with Marr Technologies B.V. ("Marr"), our strategic partner and the Company's largest investor, whose introductions and coordination directly facilitated this approval. We look forward to continuing to work with Marr as we establish our distribution system in the Russian Federation. We plan to utilize their expertise in this region in support of our sales and marketing activities."
Mr. Gale continued, "Calypte is into the sales phase of its lifecycle, and given the potential size of the Russian market, we expect that it will be one of our most significant markets for sales. It is one of our highest priorities and we believe we can begin to supply the Russian market by year end. We believe strongly that the privacy and non-invasive ease of use provided by our OTC test are attributes that squarely address the needs of the Russian Federation in its plans to contain the HIV/AIDS epidemic."
Mr. Max Soulimov, Calypte Board of Directors member, commented, "I am pleased that Marr was able to help facilitate the approval of this important product for the Russian Federation. Marr has a long history within the country and is committed to improving the quality of life inside Russia. Calypte's test is a safe and effective non-invasive HIV-1/2 rapid test that can support both government HIV/AIDS awareness and treatment programs and provide a personal and private option to Russian citizens. In my opinion, the OTC oral fluid rapid test will be a strong tool in the fight against AIDS."
Mr. Marat Safin, President of The Marr Group stated, "We are pleased to have assisted Calypte in obtaining approval for its Aware(TM) HIV-1/2 Oral Fluid rapid tests. It is well documented that young people aged 15 to 29 are increasingly bearing the brunt of new HIV infections and the number of reported cases of pregnant women with HIV has continued to increase significantly over the past few years. Marr is committed to be affiliated with these efforts to ensure the availability of this non-invasive test as a key component in a comprehensive response to combating the combined challenges of HIV and injection drug use in the Russian Federation."
About the Russian Federation:
The Russian Federation is home to 143 million people. According to the 2005 AIDS Epidemic Update jointly published by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO), there are 860,000 adults living with AIDS in the Russian Federation (as of the end of 2003). The Update notes, "In early 2004, more than 80% of all officially reported HIV cases since the beginning of the epidemic had been among drug injectors. The epidemic, meanwhile, is becoming more mature. Most drug injectors are sexually active and, if HIV-infected, they can transmit the virus sexually to their casual or regular partners. About 6% of registered infections were related to sexual transmission in 2001; by 2004, that proportion had grown to 25%." The Bill and Melinda Gates Foundation consider Russia one of the "Next Wave" countries facing the largest increase in HIV/AIDS this decade. In 2004, Russia established a Country Coordinating Mechanism (CCM) to address the situation. The CCM membership includes the government, as well as NGOs, the people living with AIDS network, and UNAIDS donors. The UNAIDS/WHO Update observes, "Substantial international funding has been made available to scale up harm reduction programmes and drug treatment services." Calypte believes that its non-invasive OTC rapid test can have an immediate positive impact on the effort to increase diagnosis and treatment of HIV/AIDS in this region.
Calypte Announces Russian Federation Approval of Oral Fluid HIV Tests
Thursday September 21, 8:00 am ET
LAKE OSWEGO, Ore., Sept. 21 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the detection of antibodies to the human immunodeficiency virus (HIV) for the professional point of care (PRO) and over the counter (OTC) segments of the market announced today that it has received approval for its Aware(TM) Oral Fluid (OMT) HIV-1/2 rapid test for both PRO and OTC markets in the Russian Federation. The Russian Federation is now the second market, following the UAE, to approve the use of an HIV-1/2 test in OTC settings, permitting significantly greater access to HIV testing in these countries.
ADVERTISEMENT
The approval has been entered into the State Register of Articles of Manufacturing for Medical Purposes and Medical Technology and is valid through August 10, 2011. The approval was granted by the Minister of the Federal Service of Health Care and Social Development Control of the Ministry of Health of the Russian Federation.
Mr. Roger Gale, Calypte's Chairman and Chief Executive Officer stated, "We have worked closely with Marr Technologies B.V. ("Marr"), our strategic partner and the Company's largest investor, whose introductions and coordination directly facilitated this approval. We look forward to continuing to work with Marr as we establish our distribution system in the Russian Federation. We plan to utilize their expertise in this region in support of our sales and marketing activities."
Mr. Gale continued, "Calypte is into the sales phase of its lifecycle, and given the potential size of the Russian market, we expect that it will be one of our most significant markets for sales. It is one of our highest priorities and we believe we can begin to supply the Russian market by year end. We believe strongly that the privacy and non-invasive ease of use provided by our OTC test are attributes that squarely address the needs of the Russian Federation in its plans to contain the HIV/AIDS epidemic."
Mr. Max Soulimov, Calypte Board of Directors member, commented, "I am pleased that Marr was able to help facilitate the approval of this important product for the Russian Federation. Marr has a long history within the country and is committed to improving the quality of life inside Russia. Calypte's test is a safe and effective non-invasive HIV-1/2 rapid test that can support both government HIV/AIDS awareness and treatment programs and provide a personal and private option to Russian citizens. In my opinion, the OTC oral fluid rapid test will be a strong tool in the fight against AIDS."
Mr. Marat Safin, President of The Marr Group stated, "We are pleased to have assisted Calypte in obtaining approval for its Aware(TM) HIV-1/2 Oral Fluid rapid tests. It is well documented that young people aged 15 to 29 are increasingly bearing the brunt of new HIV infections and the number of reported cases of pregnant women with HIV has continued to increase significantly over the past few years. Marr is committed to be affiliated with these efforts to ensure the availability of this non-invasive test as a key component in a comprehensive response to combating the combined challenges of HIV and injection drug use in the Russian Federation."
About the Russian Federation:
The Russian Federation is home to 143 million people. According to the 2005 AIDS Epidemic Update jointly published by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO), there are 860,000 adults living with AIDS in the Russian Federation (as of the end of 2003). The Update notes, "In early 2004, more than 80% of all officially reported HIV cases since the beginning of the epidemic had been among drug injectors. The epidemic, meanwhile, is becoming more mature. Most drug injectors are sexually active and, if HIV-infected, they can transmit the virus sexually to their casual or regular partners. About 6% of registered infections were related to sexual transmission in 2001; by 2004, that proportion had grown to 25%." The Bill and Melinda Gates Foundation consider Russia one of the "Next Wave" countries facing the largest increase in HIV/AIDS this decade. In 2004, Russia established a Country Coordinating Mechanism (CCM) to address the situation. The CCM membership includes the government, as well as NGOs, the people living with AIDS network, and UNAIDS donors. The UNAIDS/WHO Update observes, "Substantial international funding has been made available to scale up harm reduction programmes and drug treatment services." Calypte believes that its non-invasive OTC rapid test can have an immediate positive impact on the effort to increase diagnosis and treatment of HIV/AIDS in this region.
For those of us in AURC-
Source: Aurus Corporation
Aurus Increases Production and Acquires Krong Ltd. With Its 2.8 Million Ounces of Gold Reserves
Thursday September 21, 9:00 am ET
NEW YORK, NY--(MARKET WIRE)--Sep 21, 2006 -- Aurus Corporation (Other OTC:AURC.PK - News) announced today that it has acquired all the outstanding shares of Krong Ltd. which assets include a production plant with 2,800,000 ounces of gold reserves.
ADVERTISEMENT
"We are very enthusiastic with the possibilities presented with the acquisition of Krong Ltd. Our proven reserves combined with theirs will add up to over 7 million ounces and therefore will make AURUS one of the new leaders in the industry," said Mr. Gerald Parkin, President of Aurus Corp. "Their production plant and the technology employed for the extraction of gold tailings is exceptional and will assure us an edge which will enable us to increase production dramatically," further added Mr. Parkin. Krong Ltd. has a unique technology in treating tailings and this method shall be used in extracting ore from the other reserves of gold tailings owned by Aurus as well as from other sites throughout the federation of Russia.
About Aurus Corporation
Aurus Corporation is a publicly traded mining holding company with several precious metal properties with over 5 million ounces in gold reserves, trading under the ticker symbol AURC on the US Pink Sheets market. Aurus seeks to continue acquire proven gold and other precious metal reserves in Russia and other emerging counties and operate its mines through joint ventures and or partnerships.
About Krong Ltd.
Krong Ltd. is a privately owned company founded in 1997. It is a fully operational mining extracting and processing enterprise situated within 125 miles from Moscow. The tailings represent a total of 80,000 tons of material laying on the surface; engineering reports demonstrate an average of 0.69 gms/ Ton. The enterprise has developed unique technologies which allow the extraction of metals from tailings and, in addition, it uses the waste remaining after the process to make building materials. There is no comparable technology in the world.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
Contact:
Contact:
Gerald Parkin
President
Aurus Corporation
gparkin@auruscorp.com
514-591-3666
http://www.auruscorp.com
--------------------------------------------------------------------------------
Source: Aurus Corporation
I did not see this posted here-apologize if it has:
StockTargets Inc.: Investor targets increase on NanoViricides, Inc. stock (Pink Sheets: NNVC) following a recent analyst recommendation
By M2
Last Update: 9/7/2006 1:11:22 PM Data provided by
Sep 07, 2006 (M2 PRESSWIRE via COMTEX) -- Geneva, Switzerland, and Dover, Delaware, USA - StockTargets, Inc., a private Swiss company and an innovator in investor sentiment tracking on listed stocks, measured a firm shift in investor targets over the past 2 days on NanoViricides, Inc. (Pink Sheets: NNVC), following a new recommendation.
Investor sentiment and forecast shows a substantial increase, and remains resolutely positive on the stock's prospects, following the latest news and a revaluation of the company by TTS Zurich. Investors now forecast the stock rising to approximately US$ 3.34 during the next 12 months. The StockTargets consensus 12 months target was US$ 2.95 recently.
The 12 months target by TTS Zurich for the stock is US$ 5.50. These different targets can be reviewed by clicking the following link: http://www.stocktargets.com/cgi-bin/ticker.pl?command=nnvc.pk. Targets indicators on stocks are an aggregate of all the news, sentiment and forecasts available on the company at a given moment in time, as perceived by investors. NanoViricides, Inc. website is http://www.nanoviricides.com.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types: HIV, HCV, Herpes, Asian (bird) flu and Influenza. A nanoviricide(TM) is a specially designed, flexible, nanomaterial with or without an encapsulated active pharmaceutical ingredient and a targeting ligand to a specific type of virus, like a guided missile.
About StockTargets, Inc.
StockTargets, Inc. (http://www.stocktargets.com) is an investment banking and investor relations firm. Its Web site records all participants' sentiment, expressed as targets by its users. The StockTargets system, by building an investor sentiment indicator, attempts to gather and determine an measurement of all entries of users. The user's consensus target can be compared to targets provided by professionals, such as brokerage firms, analysts or fund managers. StockTargets Inc. was founded in 2005.
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. All trademarks mentioned in this text are properties of their respective owners.
CONTACT: Sean Kelly, StockTargets Inc. Tel: +41 22 700 7648
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
CEL-SCI Corporation Releases Letter to Shareholders
By PR Newswire
Last Update: 9/20/2006 9:40:30 AM Data provided by
VIENNA, Va., Sept 20, 2006 /PRNewswire-FirstCall via COMTEX/ -- The following letter is being released by CEL-SCI CORPORATION (CVM) to its shareholders:
Dear Fellow Shareholders:
Many of us invest in biotechnology because of its life changing possibilities and its enormous potential for financial return. We all know that the development of a biotech drug takes a long time, is difficult and costs many millions of dollars. Yet most of us are willing to wait for the potential "home run" on our investment as long as the data looks good. However, the cyclical and at times completely illogical treatment of biotechnology stocks by the investment community challenges the commitment of even the most dedicated of investors.
For this reason we are very pleased to point out that CEL-SCI's share price has outperformed the vast majority of its small and mid cap brethrens, albeit with enormous cyclical volatility, over the last few years. Since high volatility will never be eliminated from biotech stocks like CEL-SCI, we must learn to use it to our advantage. I recently purchased more stock in the open market because I believe that the present price represents a great opportunity.
In the spring of 2003 CEL-SCI's financial health looked rather bleak, our stock price hit an all time low and few people believed in our ability to survive, much less rebound. Nevertheless, despite a stock market environment that has been quite unfriendly to small and medium sized biotechnology companies like ours, we have managed to put ourselves on good financial footing and increased our share price by several hundred percent; and that is after CEL-SCI's stock price pulled back from its substantially higher level in the spring of 2006. We survived, and indeed improved our position by persistently and carefully following our plan for building shareholder value and obeying the following rule. "FOLLOW THE DATA, THE DATA NEVER LIE."
The data for CEL-SCI's products point to a very positive future for our company. Furthermore, based upon our most recent survival data and our cautious and deliberate way of proceeding, we believe that we will continue to build value for our shareholders. Management's sizable investment in CEL-SCI gives us added incentive to do so.
We aim to make the first line cancer treatment more successful through the addition of our cancer drug Multikine(R). Multikine will be a major breakthrough in therapy for cancer patients if we can confirm the increased patient survival data from our Phase II clinical studies in the planned global Phase III clinical study that has already received the go-ahead by the Canadian authorities. Simplistically, would you rather have a 65 - 70% chance of survival with our Multikine or a 50% chance of survival without our Multikine? When we can prove this kind of clinical benefit to patients, shareholder value creation will need no further explanation.
We believe that the market for Multikine may quickly expand beyond the original head and neck cancer indication. The product has already been shown to be very safe, and it is very probable that clinical trials will be conducted with Multikine to examine its usefulness in treating other diseases in which the affected patients might benefit by the addition of Multikine to their overall treatment. Furthermore, the use of Multikine, especially in cancer, would save the health care system money, most likely a lot of money, as fewer patients will have recurrence of their cancer, and thus fewer patients will need to be treated. In short, Multikine could become a very important addition to current cancer treatments.
In the last 18 months we have achieved a number of very important milestones for Multikine. We have published the mechanism of action in the Journal of Clinical Oncology, a highly recognized, leading peer-reviewed cancer publication. We have been granted an important new patent on Multikine, and we received a no objection letter (NOL) from the highly regarded Canadian regulators for our Multikine Global Phase III head and neck cancer clinical trial. Last, but not least, we presented data at the "Vaccine Discovery and Commercialization" conference in Philadelphia which indicate that the addition of Multikine prior to the standard of care treatment resulted in a 33-40% improvement in the median survival at 3 1/2 years after surgery. Survival is the "gold standard" for testing in cancer.
Our CEL-1000 drug has also received a fair amount of attention. It has shown protection in animals against a number of diseases such as herpes virus, viral encephalitis, malaria and leishmania. Based on these data, the U.S. government became interested in its potential for use against avian flu. We believe that CEL-1000 may have the best avian flu potential in two areas, one, as an adjuvant to make vaccines more effective and two, as an adjunct to other antiviral therapies. Either of these uses holds great promise for CEL-1000 as a product.
We cannot say that the past years have been without difficulties, far from it, but we have been able to overcome any obstacles that we have encountered. We believe that future obstacles will also be dealt with in the same manner. If developing new medicines for cancer were easy, cancer would have been defeated long ago; after all, President Nixon declared the war on cancer 36 years ago. Yet cancer is the second leading cause of death in the U.S. today and, if the trend continues, it is expected to become the leading cause of death in the next few years.
Today we continue to believe that our CEL-SCI shares are not fully valued by the market place, an unhappy occurrence for existing shareholders, but a great opportunity for new shareholders. This is not an uncommon phenomenon in biotechnology investing and was seen often during the early days of Amgen or Genentech, today's leading biotechnology companies. Now almost everybody wishes that they had been long-term investors in Amgen or Genentech since these companies turned out to be great investments. In hindsight the successes of these biotech leaders may appear to have been easy, but an examination of their early history reveals that things did not always go their way. Until 2003 Genentech seemed to be the only one who believed in Avastin, its new blockbuster cancer drug. These companies succeeded because they were persistent and they followed the data. We plan to do the same.
What is the value of a non-toxic cancer drug that enhances survival? To cancer patients it is immeasurable. To investors it is so big that they want to be invested in the company that owns it. That is why I have invested so much of my own money in CEL-SCI, with new stock purchases just a short time ago.
Our Phase II data suggest that we have a cancer compound that may significantly increase survival in patients with advanced primary head and neck cancer. Our Phase III trial is meant to prove this survival benefit in a statistically significant manner to get Multikine approved for sale.
In short, we hope to be able to build significant shareholder value by conducting our important work in a deliberate and methodical manner and always following the data. This has worked for us in the past few years and it should continue to work for us in the future as well. We thank you for your support.
When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K for the year ended September 30, 2005. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460.
SOURCE CEL-SCI Corporation
gwikley-I assume you are quoting from this post?
Posted by: lentinman
In reply to: IH Admin [Matt] who wrote msg# 73735 Date:9/19/2006 2:34:01 AM
Post #of 73750
SLJB:
Amazing that anyone could even begin to try to read that many posts - much less comprehend them.... although "LOL" and ".17x.18" and "To da moon" don't use up a lot of brain cells.
I don't know who posts the most on the board, but this guy has his share.
http://www.investorshub.com/boards/profile.asp?User=80502
Len
Peter Lynch "Beating the street": "Buying a cyclical after several years of record earnings and when the p/e ratio has hit a low point is a proven method for losing half your money in a short period of time."
3dcg-already in SLJB from .022, just looking for opinions after the CEO letter last night. Does one hold or fold?
Comments please on SLJB-
Posted by: Stock H.O.G.
In reply to: None
Date:9/15/2006 12:03:27 PM
Post #of 81339
Sulja Initiatives Status Report - Updated 9/15/06 12:00 p.m. EST
This should help the new investors now posting!
**************************************************
SCORECARD:
Potential Upcoming PRs = 14
Initiatives Complete = 14
Initiatives Still a Work in Progress = 14
**************************************************
LIST OF COMPLETED INITIATIVES:
1) Balance Sheet: Complete Balance Sheet, which is needed in order to complete the audit.
Status: Complete
Press Release Status: Released
**************************************************
2) Asset Move Clearance from Dubai Gov't: The company has received the official clearance to move the assets from Dubai to NV.
Status: Complete
Press Release Status: Released
**************************************************
3) Asset Move Pay creditors and liens: Lawyers have paid all creditors and liens on the assets.
Status: Complete
Press Release Status: Released
**************************************************
4) Asset Move to State of NV: Provide the State of NV the assets, forward balance sheet to auditors.
Status: Complete
Press Release Status: Released
**************************************************
5) Investor Relations New Office: The company will open another investor relations office. Working with a firm in NYC.
Status: Complete
Press Release Status: Released
**************************************************
6) Investor Relations - Shares: "No more shares being offered by Sulja". (i.e. No Dilution). Company to publish share structure.
Status: Complete
Press Release Status: Released
**************************************************
7) Financing: Wessal International to arrange for private financing of 25 million for Sulja.
Status: Complete
Press Release: Released
**************************************************
8) Exchanges: Clearly outline the exchange upward path that will be taken (i.e. Pink Sheets to OTCBB to NASDAQ)
Status: Complete
Press Release: Released
**************************************************
9) Deals - Cement: The company will be distributing a major amount of cement to Dubai. The conservative estimated revenue is 180 million in the next 12 months. Contract finalized and revenues increased to $350 million a year.
Status: Complete
Press Release Status: Released
**************************************************
10) Deals - Middle East Construction Project: Estimated revenue of 124 million in the next 12 months.
Status: Complete, Project is a WIP
Press Release Status: Released
**************************************************
11) Auditors: The company is in negotiations with KPMG and PWC (2 of the Big 4 Accounting Firms) to take over as their auditors/financial advisors.
Status: Complete
Press Release Status: Released
**************************************************
12) CEO Letter: Address shareholders with regards to calling customers in order to validate/obtain information.
Status: Complete
Press Release Status: Released
**************************************************
13) New CEO: Announce the appointment of a new CEO, replacing Steve Sulja.
Status: Complete
Press Release Status: Released
**************************************************
14) New CEO: CEO to reinforce that the share structure will not change (i.e. no dilution).
Status: Complete
Press Release Status: Released
**************************************************
**************************************************
LIST OF INITIATIVES THAT ARE A WORK IN PROGRESS:
1) Investment: Wessal International purchasing 25% of Sulja in open market.
Status: Work in Progress (they may have started already)
Press Release Status: Released/Upcoming
**************************************************
2) Earnings 2006: Revenue: 65,487,679 Net Profit: 15,000,000 - Audit the 2006 (possibly 2005) Financials
Status: Work in Progress (released but unaudited, to be completed on Sept 17th or 18th, 2006)
Press Release Status: Released/Upcoming
**************************************************
3) Earnings 2007: Estimate Revenue: 307,007,451 Net Profit: 93,951,965
Status: Work in Progress (does not include new deals recently announced, so the Pro Forma must be updated)
Press Release Status: Upcoming
**************************************************
4) Exchanges - Dubai: Company is working with one of the largest investment banks in order to be listed on the Dubai International Financial Exchange.
Status: Work in Progress
Press Release Status: Upcoming
**************************************************
5) Exchanges - OTCBB: The company is looking to move from the Pink Sheets to the OTCBB. Must file form 10 post audit. Company quote: "Our shareholders will soon see why Sulja Bros did not need to reverse split the stock to meet our up listing goals".
Status: Work in Progress
Status Report Status: Upcoming
**************************************************
6) Exchanges - NASDAQ: Once on the OTCBB, the company is looking to move to the NASDAQ.
Status: Work in Progress
Status Report Status: Upcoming
**************************************************
7) Deals - Steel: There is a need for large amounts of structural steel in Dubai. The company is working on a deal.
Status: Work in Progress
Press Release Status: Upcoming
**************************************************
8) Deals - Provide details of new deals mentioned in Aug 23 PR
Status: Work in Progress
Press Release Status: Upcoming
**************************************************
9) Design Depots - Setup a Design Depot in Dubai
Status: Work in Progress
Press Release Status: Released/Upcoming
**************************************************
10) Design Depots - Setup 3 Design Depots in the U.S.
Status: Work in Progress
Press Release Status: Released/Upcoming
**************************************************
11) Interview: Complete the MN1 Interview on or about Oct 3, 2006
Status: Work in Progress
Press Release Status: Released/Upcoming
**************************************************
12) Loss of Larger Client: Repair the relationship with one of Sulja's larger clients due to the recent poor judgement of certain so called investors. Advise shareholders when relationship is repaired.
Status: Work in Progress (IR firm confirmed all is well again)
Press Release Status: Upcoming
**************************************************
13) New Website: Revamp and implement a new Sulja website, which also allows investors to post their ideas, concerns, etc.
Status: Work in Progress (ETA Sept 21, 2006)
Press Release Status: Upcoming
**************************************************
14) Merger: Possible merger with Consultech Mid-West.
Status: Unknown
Press Release Status: Unknown
**************************************************
and of course this is all IMO!!!
All of the above is in my opinion only. Please do not buy or sell based on what I have written.
So, Ohio, are you buying today?
I sold my .022 lot this morning at .20 also but am not holding all freebies as I have several .07,s remaining. I have learned the hard way not to become a hog-only a pig,lol.
I agree benz and many posters chatting (useless posts) as if they were teenagers on a phone.
SLJB PR delay-
Sulja Bros. Building Supplies Ltd. Announces a Delay in the CEO Statement to Be Posted Today
By Market Wire
Last Update: 9/18/2006 3:21:53 PM Data provided by
WINDSOR, ON, Sep 18, 2006 (MARKET WIRE via COMTEX) -- Sulja Bros. Building Supplies Ltd. (PINKSHEETS: SLJB). A new CEO statement was to be updated on www.suljabros.com this morning; unfortunately due to unforeseeable circumstances, CEO Petar Vucicevich's statement will be delayed, until later on this evening.
This contains forward-looking information within the meaning of The Private Securities Litigation Act of 1995. Forward-looking statements may be identified through the use of words such as "expects," "will," "anticipates," "estimates," "believes," or statements indicating certain actions: "may," "could," "should" or "might occur." Such forward-looking statements involve certain risks and uncertainties. The actual result may differ materially from such forward-looking statements. The company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results (expressed or implied) will not be realized.
SOURCE: Sulja Bros. Building Supplies Ltd.
By: frpt100k
17 Sep 2006, 10:53 AM EDT
Msg. 88024 of 88325
(This msg. is a reply to 88023 by frpt100k.)
Jump to msg. #
Can a good Muslim be a good American? I sent that question to a friend who worked in Saudi Arabia for 20 years. The following is his reply:
Theologically - no. Because his allegiance is to Allah, the moon god of Arabia.
Religiously - no. Because no other religion is accepted by his Allah except Islam
(Quran, 2:256)
Scripturally - no. Because his allegiance is to the five pillars of Islam and the Quran
(Koran).
Geographically - no. Because his allegiance is to Mecca, to which he turns in prayer five times a day.
Socially - no. Because his allegiance to Islam forbids him to make friends with Christians or Jews.
Politically - no. Because he must submit to the mullah (spiritual leaders), who teach annihilation of Israel and Destruction of America, the great Satan.
Domestically - no. Because he is instructed to marry four women and beat and scourge his wife when she disobeys him (Quran
4:34).
Intellectually - no. Because he cannot accept the American Constitution since it is based on Biblical principles and he believes the Bible to be corrupt.
Philosophically - no. Because Islam, Muhammad, and the Quran do not allow freedom of religion and __expression. Democracy and Islam cannot coexist. Every Muslim government is either dictatorial or autocratic.
Spiritually - no. Because when we declare "one nation under God," the Christian's God is loving and kind, while Allah is NEVER referred to as heavenly father, nor is he ever called love in The Quran's 99 excellent names.
Therefore after much study and deliberation....perhaps we should be very suspicious of ALL MUSLIMS in this country. They obviously cannot be both "good" Muslims and good Americans. Call it what you wish....it's still the truth. If you find yourself intellectually in agreement with these statements, perhaps you will share this with your friends. The more who understand this, the better it will be for our country and our future.
Pass it on Fellow Americans. The religious war is bigger than we know or understand.
- - - - -
NDOL News
Sep 18, 2006 12:57:00 PM
NEW YORK, NY -- (MARKET WIRE) -- 09/18/06 -- Nord Oil International (PINKSHEETS: NDOL) announced that it has changed its name to North West Oil Group as provided in the merger agreement. The relevant ticker symbol shall also be changed. This is a step closer in the Company's quest to go to another exchange.
About North West Oil Group
North West Oil Group is a non reporting, publicly traded Oil & Gas company trading under the ticker symbol NDOL on the US Pinksheets market as well as on the Frankfurt Exchange under symbol CXIA. Nord Oil International and the North West Oil Group merged on May 11, 2006. The company is in the process of filing all regulatory statements to obtain a new ticker symbol. The company presently produces over 120,000 Metric Tons of crude oil yearly.
Important Information About Forward-Looking Statements
All statements in this news release that are other than statements of historical facts are forward-looking statements, which contain our current expectations about our future results. Forward-looking statements involve numerous risks and uncertainties. We have attempted to identify any forward-looking statements by using words such as "anticipates," "believes," "could," "expects," "intends," "may," "should" and other similar expressions. Although we believe that the expectations reflected in all of our forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct.
A number of factors may affect our future results and may cause those results to differ materially from those indicated in any forward-looking statements made by us or on our behalf. Such factors include our limited operating history; our need for significant capital to finance internal growth as well as strategic acquisitions; our ability to attract and retain key employees and strategic partners; our ability to achieve and maintain profitability; fluctuations in the trading price and volume of our stock; competition from other providers of similar products and services; and other unanticipated future events and conditions.
Contact:
Ken Maciora
Empire Relations Group
516-750-9719
km@empirerelations.com
SLJB-now up $8,640
Re: Updates-
SLJB-paper gain of $7,560
NDOL-paper loss of 6,625
AURC-about even
sometimes; never did trust anyone who did not know difference between "their","there", and they,re",lol.